L-arginine: a novel therapy for coronary artery disease?

Bibliography

• MURRAY CJL, LOPEZ AD: Mortality by cause for eight regions of the world: Global Burden of Disease Study. Lancet (1997) 349:1269–1276.
   PubMed Web of Science ®Google Scholar
• MURRAY CJL, LOPEZ AD: Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet (1997) 349:1498–1504.
   PubMed Web of Science ®Google Scholar
• Editorial. Lancet (1998) 352:1795
   PubMed Web of Science ®Google Scholar
• LLOYD-JONES DM, LARSON MG, BEISER A, LEVY D: Lifetime risk of developing coronary heart disease. Lancet (1999) 353:89–92.
   PubMed Web of Science ®Google Scholar
• FUSTER V: Mechanisms leading to myocardial infarc-tion: insights from studies of vascular biology. Circula-tion (1994) 90:2126–2146.
   PubMed Web of Science ®Google Scholar
• ROSS R: The pathogenesis of atherosclerosis: aperspective for the 1990's. Nature (1993) 362:801–808.
   PubMed Web of Science ®Google Scholar
• FUSTER V, BADIMON L, BADIMON JJ, CHESEBORO JH:The pathogenesis of coronary artery disease and the acute coronary syndromes (Part 11). New Engl. J. Med. (1992) 326:310–318.
   PubMed Web of Science ®Google Scholar
• LUDMER PL, SELWYN AP, SHOOK TL et al: Paradoxicalvasoconstriction induced by acetylcholine in athero-sclerotic coronary arteries. N Engl. J. Med. (1986) 315:1046–1051.
   PubMed Web of Science ®Google Scholar
• QUYYUMI AA, DAKAK N, MULCAHY D et al.: Nitric oxide activity in the atherosclerotic human coronary circulation. J. Am. Coll. Cardiol (1997) 29:308–317.
   PubMed Web of Science ®Google Scholar
• WITZTUM JL: The oxidation hypothesis of atheroscle-rosis. Lancet (1994) 344:793–795.
   PubMed Web of Science ®Google Scholar
• OTSUJI S, NAKAJIMA 0, WAKU S et al.: Attenuation ofacetylcholine-induced vasoconstriction by t-arginine is related to the progression of atherosclerosis. Am. Heart J. (1995) 129:1094–1100.
   Google Scholar
• TREASURE CB, KLEIN JL, WEINTRAUB WS et al.: Benefi-cial effects of cholesterm-lowering therapy on the coronary endothelium in patients with coronary artery disease. N Engl. J. Med. (1995) 332:481–487.
   PubMed Web of Science ®Google Scholar
• ANDERSON TJ, MEREDITH IT, YEUNG AC, FREI B, SELWYN AP, GANZ P: The effect of cholesterm-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion. N. Engl. J. Med. (1995) 332:488–493.
   PubMed Web of Science ®Google Scholar
• PANZA JA, QUYYUMI AA, CALLAHAN TS, EPSTEIN SE:Effect of antihypertensive treatment on endotheliat-dependent vascular relaxation in patients with essential hypertension. J. Am. Coll. Cardiol. (1993) 21:1145–1151.
   PubMed Web of Science ®Google Scholar
• LEVINE GN, FRET B, KOULOURIS SN, GERHARD MD, KEANEY JF JR, VITA JA: Ascorbic acid reverses endothe-lial vasomotor dysfunction in patients with coronary artery disease. Circulation (1996) 93:1107–1113.
   PubMed Web of Science ®Google Scholar
• GILLIGAN DM, SACK MN, GUETTA V et al.: Effect ofantioxidant vitamins on low-density lipoprotein oxidation and impaired endothelium-dependent vasodilation in patients with hypercholesterolemia. J. Am. Coll. Cardiol (1994) 24:1611–1617.
   PubMed Web of Science ®Google Scholar
• GUETTA V, CANNON RO III: Cardiovascular effects ofestrogen and lipid-lowering therapies in postmeno-pausal women. Circulation (1996) 93:1928–1937.
   PubMed Web of Science ®Google Scholar
• LIEBERMAN EH, GERHARD MD, UEHATA A et al.: Estrogen improves endothelium-dependent, flow-mediated vasodilation in postmenopausal women. Ann. Intern. Med. (1994) 121:936–941.
   PubMed Web of Science ®Google Scholar
• LERMAN A, BURNETT JC JR., HIGANO ST, MCKINLEY LJ,HOLMES DR JR: Long-term Larginine supplementation improves smalt-vessel coronary endothelial function in humans. Circulation (1998) 97:2123–2128.
   Google Scholar
• DREXLER H, ZEIHER AM, MEINER K, JUST H: Correctionof endothelial dysfunction in coronary microcircula-tion of hypercholesterolaemic patients by Larginine. Lancet (1991) 338:1546–1550.
   PubMed Web of Science ®Google Scholar
• EGASHIRA K, HIROOKA Y, KUGA T, MOHRI M, TAKESHITA A: Effects of Larginine supplementation on endothelium-dependent coronary vasodilation in patients with angina pectoris and normal coronary arteriograms. Circulation (1996) 94:130–134.
   PubMed Web of Science ®Google Scholar
• CEREMUZYNSKI L, CHAMIEC T, HERBACZYNSKA-CEDROK: Effect of supplemental oral Larginine on exercise capacity in patients with stable angina pectoris. Am. J. Card. (1997) 80:331–333.
   PubMed Web of Science ®Google Scholar
• BOGER RH, BODE-BOGER SM, THIELE W, CREUTZIG A,ALEXANDER K, FROLICH JC: Restoring vascular nitric oxide formation by Larginine improves the symptoms of intermittent claudication in patients with periph-eral arterial occlusive disease. J. Am. Coll. Cardiol. (1998) 32:1336–1344.
   PubMed Web of Science ®Google Scholar
• KOIFMAN B, WOLLMAN Y, BOGOMOLNY N et al.: Improvement of cardiac performance by intravenous infusion of t-arginine in patients with moderate congestive heart failure. J. Am. Coll. Cardiol. (1995) 26:1251–1256.
   PubMed Web of Science ®Google Scholar
• MCNAMARA DB, BEDI B, AURORA H et al.: Larginineinhibits balloon catheter-induced intimal hyperplasia. Biochem. Biophys. Res. Commun. (1993) 193:291–296.
   PubMed Web of Science ®Google Scholar
• SCHWARZACHER SP, LIM TT, WANG B et al. Local intramural delivery of t-arginine enhances nitric oxide generation and inhibits lesion formation after balloon angioplasty. Circulation (1997) 95:1863–1869.
   PubMed Web of Science ®Google Scholar
• PEARSON PJ, UN PJ, SCHAFF HV: Global myocardial ischemia and reperfusion impair endothelium-dependent relaxations to aggregating platelets in the canine coronary artery. J. Thorac. Cardiovasc. Surg. (1992) 103:1147–1154.
   PubMed Web of Science ®Google Scholar
• MA X, WEYRICH AS, LEFER DJ, LEFER AM: Diminished basal nitric oxide release after myocardial ischemia and reperfusion promotes neutrophil adherence to coronary endothelium. Circ. Res. (1993) 72:403–412.
   PubMed Web of Science ®Google Scholar
• VINTEN-JOHANSEN J, SATO H, ZHAO ZQ: The role of nitric oxide and NO-donor agents in myocardial protection from surgical ischemic-reperfusion injury. Int. J. Cardiol. (1995) 50:273–281.
   PubMed Web of Science ®Google Scholar
• SATO H, ZHAO ZQ, MCGEE S et al.: Supplemental Larginine during cardioplegic arrest and reperfusion avoids regional postischemic injury. J. Thorac. Cardio-vasc. Surg. (1995) 110:302–314.
   PubMed Web of Science ®Google Scholar
• NAKANISHI K, VINTEN-JOHANSEN J, LEFER DJ, ZHAO Z et Intracoronary t-arginine during reperfusion improves endothelial function and reduces infarct size. Am. J. Physiol. (1992) 263:H1650–H1658.
   PubMed Web of Science ®Google Scholar
• ZHU B, SUN Y, SIEVERS R et al.: Larginine decreases infarct size in rats exposed to environmental tobacco smoke. Am. Heart J. (1996) 132:91–100.
   PubMed Web of Science ®Google Scholar
• ENGELMAN DT, WANTANABE M, MAULIK N et al.: t-arginine reduces endothelial inflammation and myocardial stunning during ischemia/reperfusion. Ann. Thorac. Surg. (1995) 60:1275–1281
   PubMed Web of Science ®Google Scholar
• FURCHGOTT RF, ZAWADZKI JV: The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature (1980) 288:373–376.
   PubMed Web of Science ®Google Scholar
• QUYYUMI AA: Circadian variation in myocardial ischemia: pathophysiological mechanisms. In: Silent Myocardial Ischaemia Stern S (Ed.) Martin Dunitz Ltd., London (1998):159–174
   Google Scholar
• BUSSE R, FLEMING I: Regulation and functional consequences of endothelial nitric oxide formation. Ann. Med. (1995) 27:331–340.
   PubMed Web of Science ®Google Scholar
• PALMER RMJ, FERRIGE AG, MONCADO S: Nitric oxide accounts for the biological activity of the endothelium-derived relaxing factor. Nature (1987) 327:524–526.
   PubMed Web of Science ®Google Scholar
• PALMER RMJ, ASHTON DS, MONCADA S: Vascular endothelial cells synthesize nitric oxide from LArginine. Nature (1988) 333:664–666.
   PubMed Web of Science ®Google Scholar
• MONCADA S, HIGGS EA: The LArginine-nitric oxide pathway. N Engl. J. Med. (1993) 329:2002–2012.
   PubMed Web of Science ®Google Scholar
• BREDT DS, HWANG PM, GLATT CE, LOWENSTEIN C, REED RR, SNYDER SH: Cloned and expressed nitric oxide synthase structurally resembles cytochrom P-450 reductase. Nature (1991) 351:714–718.
   PubMed Web of Science ®Google Scholar
• REES DD, PALMER RMJ, SHULZ R, HODSON HK, MONCADO S: Characterization of three inhibitors of endothelial nitric oxide synthase in vitro and in vivo. Br. J. Pharmacol (1990) 101:746–752.
   PubMed Web of Science ®Google Scholar
• MONCADA S, PALMER RMJ, HIGGS EA: Nitric oxide: Physiology, pathophysiology, and pharmacology. Pharmacol. Rev. (1991) 43:109–142.
   PubMed Web of Science ®Google Scholar
• VALLANCE P, LEONE A, CALVER A, COLLIER J, MONCADO S: Endogenous dimethylarginine as an inhibitor of nitric oxide synthesis. J. Cardiovasc. Pharmacol. (1992) 20\(Suppl. 12):S60–S62.
   Google Scholar
• YU X, LI Y, XIONG Y: Increase of an endogenous inhibitor of nitric oxide synthesis in serum of high cholesterol fed rabbits. Life Sci. (1994) 54:753–758.
   PubMed Web of Science ®Google Scholar
• BOGER RH, BODE-BOGER RH, THIELE W, JUNKER W,ALEXANDER K, FROLICH JC: Biochemical evidence for impaired nitric oxide synthesis in patients with peripheral arterial occlusive disease. Circulation (1997) 95:2068–2074.
   PubMed Web of Science ®Google Scholar
• KURZ S, HARRISON DG: Insulin and the arginine paradox. J Clin. Invest. (1997) 99:369–370.
   PubMed Web of Science ®Google Scholar
• BODE-BOGER SM, BOGER RH, ALFKE H et al.: t-arginine induces nitric oxide-dependent vasodilation in patients with critical limb ischemia. A randomized, controlled study. Circulation (1996) 93:85–90.
   PubMed Web of Science ®Google Scholar
• MICROMEDEX: 1974–1998, Volume 98
   Google Scholar
• QUYYUMI AA, MULCAHY D, ANDREWS NP, HUSAIN S,PANZA JA, CANNON RO III: Coronary vascular nitric oxide activity in hypertension and hypercholestero-lemia: comparison of acetylcholine and substance P. Circulation (1997) 95:104–110.
   PubMed Web of Science ®Google Scholar
• PANZA JA, CASINO PR, BADAR DM, QUYYUMI AA: Effectof increased availability of endothelium-derived nitric-oxide precursor on endothelium-dependent vascular relaxation in normal subjects and in patients with essential hypertension. Circulation (1993) 87:1475–1481.
   PubMed Web of Science ®Google Scholar
• QUYYUMI AA, DAKAK N, ANDREWS NP et al.: Nitricoxide activity in the human coronary circulation: impact of risk factors for coronary atherosclerosis. J. Clin. Invest. (1995) 95:1747–1755.
   PubMed Web of Science ®Google Scholar
• EGASHIRA K, INOU T, HIROOKA Y et al: Impaired coronary blood flow response to acetylcholine in patients with coronary risk factors and proximal atherosclerotic lesions. J. Clin. Invest. (1993) 91:29–37.
   PubMed Web of Science ®Google Scholar
• VITA JA, TREASURE CB, NABEL EG et al.: Coronaryvasomotor response to acetylcholine relates to risk factors for coronary artery disease. Circulation (1990) 81:491–497.
   PubMed Web of Science ®Google Scholar
• CELERMAJER DS, SORENSON KE, SPIEGELHALTER DJ, GEORGAKOPOULOS D, ROBINSON J, DEANFIELD JE: Aging is associated with endothelial dysfunction in healthy men years before the age-related decline in women. J. Am. Coll Cardiol (1994) 24:471–476.
   PubMed Web of Science ®Google Scholar
• BEST PJM, BERGER PB, MILLER VM, LERMAN A: The effectof estrogen replacement therapy on plasma nitric oxide and endothelin-1 levels in postmenopausal women. Ann. Int. Merl. (1997) 128:285–288.
   Web of Science ®Google Scholar
• MANCINI GBJ, HENRY GC, MACAYA C et al.: Angiotensin-converting enzyme inhibition with quinipril improves endothelial vasomotor dysfunc-tion in patients with coronary artery disease: the TREND (Trial on Reversing Endothelial Dysfunction) Study. Circulation (1996) 94:258–265.
   PubMed Web of Science ®Google Scholar
• MAXWELL AJ, COOKE JP: Cardiovascular effects oft-arginine. Curr. Opin. Neph. Hyper. (1998) 7:63–70.
   PubMed Web of Science ®Google Scholar
• COOKE JP, SINGER AH, TSAO PS, ZERA P, ROWAN RA,BILLINGHAM ME: Anti-atherogenic effects of Larginine in the hypercholesterolemic rabbit. J. Clin. Invest. (1992) 90:1168–1172.
   PubMed Web of Science ®Google Scholar
• AJI W, RAVALLI S, SZABOLCS M et al.: Larginine preventsxanthoma development and inhibits atherosclerosis in LDL receptor knockout mice. Circulation (1997) 95:430–437.
   PubMed Web of Science ®Google Scholar
• BOGER RH, BODE-BOGER SM, BRANDES RP et al.: Dietary Larginine reduces the progression of athero-sclerosis in cholesterm-fed rabbits: comparison with lovastatin. Circulation (1997) 96:1282–1290.
   PubMed Web of Science ®Google Scholar
• CANDIPAN RC, WANG BY, BUITRAGO R, TSAO PS, COOKE JP: Regression or progression. Dependency on vascular nitric oxide. Arterioscler. Thromb. Vasc. Biol. (1996) 16:44–50.
   PubMed Web of Science ®Google Scholar
• CREAGER MA, GALLAGHER SJ, GIRERD XJ, COLEMAN SM,DZAU VJ, COOKE JP: t-arginine improves endothelium-dependent vasodilation in hypercholes-terolemic humans. J. Clin. Invest. (1992) 90:1248–1253.
   PubMed Web of Science ®Google Scholar
• CLARKSON P, ADAMS MR, POWE AJ et al.: Oral Larginineimproves endothelium-dependent dilation in hypercholesterolemic humans. J. Clin. Invest. (1996) 97:1989–1994.
   PubMed Web of Science ®Google Scholar
• WOLF A, ZALPOUR C, THEILMEIER G et al.: Dietaryt-arginine supplementation normalizes platelet aggregation in hypercholesterolemic humans. J. Am. Coll. Cardiol. (1997) 29:479–485.
   PubMed Web of Science ®Google Scholar
• QUYYUMI, AA: Does acute improvement of endothelialdysfunction in coronary artery disease improve myocardial ischemia? A double-blind comparison of parenteral D- and Larginine. J. Am. Coll. Cardiol. (1998) 32:904–911.
   PubMed Web of Science ®Google Scholar
• CHAUHAN A, MORE RS, MULLINS PA, TAYLOR G, PETCHC, SCHOFIELD PM: Aging-associated endothelial dysfunction in humans is reversed by Larginine. J. Am. Coll. Cardiol. (1996) 28:1796–1804.
   PubMed Web of Science ®Google Scholar
• CAMPISI R, CZERNIN J, SCHODER H, SAYRE JW,SCHELBERT HR: t-arginine normalizes coronary vasomotion in long-term smokers. Circulation (1999) 99:491–497.
   PubMed Web of Science ®Google Scholar
• DUBEY RK, JACKSON EK, RUPPRECHT HD, STERZEL RB:Factors controlling growth and matrix production in vascular smooth muscle and glomerular mesangial cells. Curr. Opin. Nephrol. Hypertens. (1997) 6:88–105.
   PubMed Web of Science ®Google Scholar
• CORSEAUX D, LE TOURNEAU T, SIX I et al.: Enhanced monocyte tissue factor response after experimental balloon angioplasty in hypercholesterolemic rabbit: inhibition with dietary t-arginine. Circulation (1998) 98:1776–1782.
   PubMed Web of Science ®Google Scholar
• VON DER LEYDEN HE, GIBBONS GH, MORISHITA R: Gene therapy inhibiting neointimal vascular lesion: in vivo transfer of endothelial cell nitric oxide synthase gene. Proc. Natl. Acad. ScL USA (1995) 92:1137–1141.
   PubMed Web of Science ®Google Scholar
• RECTOR TS, BANK AJ, MULLEN KA et al: Randomized, double-blind, placebo-controlled study of supple-mental oral Larginine in patients with heart failure. Circulation (1996) 93:2135–2141.
   PubMed Web of Science ®Google Scholar
• HIGASHI Y, OSHIMA T, ONO N et al.: Intravenous administration of t-arginine inhibits angiotensin-converting enzyme in humans. J. Clin. Endocrinol. Metab. (1995) 80:2198–2202.
   PubMed Web of Science ®Google Scholar
• KANNO K, HIRATA Y, EMORI T etal.: Larginine infusion induces hypotension and diruresis/natriuresis with concomitant increased urinary excretion of nitrite/nitrate and cyclic GMP in humans. Clin. Exp. Pharmacol. Physic)]. (1992) 19:619–625.
   Google Scholar
• GRYGLEWSKI RJ, GRODZINSKA L, KOSTKA-TRABKA E et al.: Treatment with Larginine is likely to stimulate generation of nitric oxide in patients with peripheral arterial obstructive disease. Wien. Klin. Wochenschr. (1996) 108:111–116.
   PubMed Web of Science ®Google Scholar
• SCHELLONG SM, BOGER RH, BURCHERT W et al.: Dose-related effect of intravenous t-arginine on muscular blood flow of the calf in patients with peripheral vascular disease: a 112150 positron emission tomography study. Clin. Sci. (1997) 93:159–165.
   PubMed Web of Science ®Google Scholar
• YAO SK, OBER JC, KRISHNASWAMI A et al.: Endogenous nitric oxide protects against platelet aggregation and cyclic flow variations in stenosed and endothelium-injured arteries. Circulation (1992) 86:1302–1309.
   PubMed Web of Science ®Google Scholar
• YAO SK, AKHTAR S, SCOTT-BURDEN T et al.: Endoge-nous and exogenous nitric oxide protect against intracoronary thrombosis and reocclusion after thrombolysis. Circulation (1995) 92:1005–1010.
   PubMed Web of Science ®Google Scholar
• BOLLI R, TRIANA JF, JEROUDI MO: Prolonged impair-ment of coronary vasodilation after reversible ischemia: evidence for microvascular stunning. Circulation (1990) 67:332–343.
   Web of Science ®Google Scholar
• QUILLEN JE, SELKE FW, BROOKS LA, HARRISON DG: Ischemia-reperfusion impairs endothelium-dependent relaxation of coronary microvessels but does not affect large arteries. Circulation (1990) 82:586–594.
   PubMed Web of Science ®Google Scholar
• LIMA JAC, JUDD RM, BAZILLE A, SCHULMAN SP, ATALARE, ZERHOUNI EA: Regional heterogeneity of human myocardial infarcts demonstrated by contrast-enhanced MRI: potential mechanisms. Circulation (1995) 92:1117–1125.
   PubMed Web of Science ®Google Scholar
• ITO H, TOMOOKA T, SAKAI N et al. Lack of myocardial perfusion immediately after successful thrombolysis: a predictor of poor recovery of left ventricular function in anterior myocardial infarction. Circulation (1992) 85:1699–1705.
   PubMed Web of Science ®Google Scholar
• ITO H, OKAMURA A, IWAKURA K et al.: Myocardial perfusion patterns related to thrombolysis in myocar-dial infarction perfusion grades after coronary angioplasty in patients with acute anterior wall myocardial infarction. Circulation (1996) 93:1993–1999.
   PubMed Web of Science ®Google Scholar
• WU KC, ZERHOUNI EA, JUDD RM et al.: The prognostic significance of microvascular obstruction by magnetic resonance imaging in patients with acute myocardial infarction. Circulation (1998) 97:765–772.
   PubMed Web of Science ®Google Scholar
• CLAEYS MJ, BOSMANS J, VEENSTRA L, JORENS P, DE RAEDT H, VRINTS CJ: Determinants and prognostic implications of persistent ST-segment elevation after primary angioplasty for acute myocardial infarction. Importance of microvascular reperfusion injury on clinical outcomes. Circulation (1999) 99:1972–1977.
   Google Scholar
• HOSHIDA S, NISHIDA M, YAMASHITA N et al.: Ameliora-tion of severity of myocardial injury by a nitric oxide donor in rabbits fed a cholesterm-rich diet. J. Am. Coll Cardiol. (1996) 27:902–909.
   PubMed Web of Science ®Google Scholar
• IKEDA K, NARA Y, TAGAMI M, YAMORI Y: Nitric oxide deficiency induces myocardial infarction in hypercholesterolaemic stroke-prone rats. Clin. Exp. Pharmacol. Physiol. (1997) 24:344–348.
   PubMed Web of Science ®Google Scholar
• MORENO H JR., NATHAN LP, METZE K etal.: Non-specific inhibitors of nitric oxide synthase cause myocardial necrosis in the rat. Clin. Exp. Pharmacol Physiol. (1997) 24:349–352.
   Google Scholar
• VINTEN-JOHANSEN J, HAMMON JW JR: Myocardial protection during cardiac surgery. In: Cardiopulmonary Bypass: Principles and Practice. Utley J, Gravlee GP (Ed.), Williams & Wilkins, New York (1993) 155–206.
   Google Scholar
• BUCKBERG GD: Strategies and logic of cardioplegicdelivery to prevent, avoid, and reverse ischemic and reperfusion damage. J. Thorac. Cardiovasc. Surg. (1987) 93:127–139.
   PubMed Web of Science ®Google Scholar
• DIGNAN RJ, DYKE CM, ABD-ELFATTAH AA et al.: Coronary artery endothelial cell and smooth muscle dysfunction after global myocardial ischemia. Ann. Thorac. Surg. (1992) 53:311–317.
   PubMed Web of Science ®Google Scholar
• MIZUNO A, BARETTI R, BUCKBERG GD etal.: Endothelial stunning and myocyte recovery after reperfusion of jeopardized muscle: a role of Larginine blood cardio-plegia. J. Thorac. Cardiovasc. Surg. (1997) 113:379–389.
   Google Scholar
• CARRIER M, PELLERIN M, PAGE PL et al.: Can Larginine improve myocardial protection during cardioplegic arrest? Results of a Phase I pilot study. Ann. Thorac. Surg. (1998) 66:108–112.
   PubMed Web of Science ®Google Scholar